Five Prime Therapeutics

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative therapeutics to improve the lives of patients with serious diseases. Our comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions us to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2001
Size (employees)
195 (est)+27%
Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US

Key People at Five Prime Therapeutics

Jim Blair

Jim Blair

Director
Aron Knickerbocker

Aron Knickerbocker

Senior Vice President and Chief Business Officer, Board of Directors
Marc Belsky

Marc Belsky

Senior Vice President and Chief Financial Officer
Lauretta Cesario

Lauretta Cesario

Vice President, Human Resources

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
2 Corporate Dr

Five Prime Therapeutics Metrics

Five Prime Therapeutics Financial Metrics

Net income (FY, 2013)

($28.9 m)

EBIT (FY, 2013)

($29.4 m)

Market capitalization (22-May-2017)

$809 m

Closing share price (22-May-2017)

$29.3

Cash (31-Dec-2016)

$7.7 m
Five Prime Therapeutics's current market capitalization is $809 m.
FY, 2013

Operating expense total

$43.2 m

EBIT

($29.4 m)

Net Income

($28.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$8.2 m$15.3 m$150 m$7.7 m

Accounts Receivable

Inventories

Current Assets

$77.7 m$151.3 m$528.3 m$440.1 m

PP&E

$3.7 m$3.8 m$4.5 m$6.2 m

Total Assets

$81.8 m$155.6 m$548.3 m$448.3 m

Accounts Payable

$348 k$1.1 m$1.9 m$334 k

Current Liabilities

$13.8 m$19.8 m$79.4 m$38.7 m

Common Stock

$17 k

Preferred Stock

Additional Paid-in Capital

$209.6 m$274.2 m$372.6 m$396.6 m

Retained Earnings

($151.6 m)($189 m)$60.6 m($5 m)

Total Equity

$58 m$433.2 m$391.6 m

Financial Leverage

1.4 x1.3 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($28.9 m)($37.4 m)$249.6 m($65.7 m)

Depreciation and Amortization

$1.7 m$1.6 m$1.7 m$1.7 m

Accounts Receivable

Inventories

Accounts Payable

($209 k)$701 k$798 k($1.6 m)

Cash From Operating Activities

($25.3 m)$15.3 m$289.1 m($79.8 m)

Purchases of PP&E

($807 k)($1.6 m)($2.4 m)($3 m)

Cash From Investing Activities

($42.2 m)($69.4 m)($238.2 m)($53.7 m)

Cash From Financing Activities

$64.3 m$61.2 m$83.8 m($8.9 m)

Income Taxes Paid

$11.4 m
Y, 2016

Financial Leverage

1.1 x

Five Prime Therapeutics Market Value History

Five Prime Therapeutics Online Presence

Five Prime Therapeutics Company Life

You may also be interested in